Logo image of KYMR

KYMERA THERAPEUTICS INC (KYMR) Stock Analyst Ratings

USA - Nasdaq - NASDAQ:KYMR - US5015751044 - Common Stock

73.41 USD
+2.25 (+3.16%)
Last: 1/29/2026, 2:08:27 PM
Buy % Consensus

88

ChartMill assigns a Buy % Consensus number of 88% to KYMR. The Buy consensus is the weighted average rating of the current analysts ratings.

  • Analysts have set a mean price target forecast of 112.64. This target is 53.44% above the current price.
  • KYMR was analyzed by 29 analysts. The buy percentage consensus is at 88. So analysts seem to be very confident about KYMR.
  • In the previous month the buy percentage consensus was at a similar level.
  • KYMR was analyzed by 29 analysts, which is quite many. So the average rating should be quite meaningful.
KYMR Historical Analyst RatingsKYMR Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -64 -58 -52 -46 -40 -34 -28 -22 -16 -10 -4 5 10 15 20 25

Price Target & Forecast

Price Low Median Mean High 73.4170.70118.32112.64144.90 - -3.69% 61.18% 53.44% 97.38%
KYMR Current Analyst RatingKYMR Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 5 10 15
Up and Down Grades
Date Firm Action Rating
2026-01-28 Barclays Maintains Overweight -> Overweight
2026-01-15 BTIG Reiterate Buy -> Buy
2026-01-06 Wolfe Research Downgrade Outperform -> Peer Perform
2025-12-22 B. Riley Securities Maintains Buy -> Buy
2025-12-16 RBC Capital Maintains Outperform -> Outperform
2025-12-11 Mizuho Maintains Outperform -> Outperform
2025-12-11 Stephens & Co. Maintains Overweight -> Overweight
2025-12-10 JP Morgan Maintains Overweight -> Overweight
2025-12-09 Leerink Partners Maintains Outperform -> Outperform
2025-12-09 BTIG Maintains Buy -> Buy
2025-12-09 Oppenheimer Maintains Outperform -> Outperform
2025-12-09 Barclays Maintains Overweight -> Overweight
2025-12-09 Wells Fargo Maintains Overweight -> Overweight
2025-12-09 Truist Securities Maintains Buy -> Buy
2025-12-09 B of A Securities Maintains Buy -> Buy
2025-12-09 Morgan Stanley Maintains Overweight -> Overweight
2025-12-09 Piper Sandler Reiterate Overweight -> Overweight
2025-12-09 Citigroup Maintains Buy -> Buy
2025-12-09 Jefferies Maintains Buy -> Buy
2025-12-09 HC Wainwright & Co. Maintains Buy -> Buy
2025-11-26 Truist Securities Maintains Buy -> Buy
2025-11-05 Barclays Maintains Overweight -> Overweight
2025-11-05 Wells Fargo Maintains Overweight -> Overweight
2025-11-05 HC Wainwright & Co. Maintains Buy -> Buy
2025-10-22 BTIG Maintains Buy -> Buy
2025-10-21 Mizuho Initiate Outperform
2025-10-17 Citigroup Maintains Buy -> Buy
2025-10-01 Oppenheimer Maintains Outperform -> Outperform
2025-09-30 Truist Securities Maintains Buy -> Buy
2025-09-18 HC Wainwright & Co. Maintains Buy -> Buy

KYMERA THERAPEUTICS INC / KYMR FAQ

Can you provide the average price target for KYMERA THERAPEUTICS INC stock?

29 analysts have analysed KYMR and the average price target is 112.64 USD. This implies a price increase of 53.44% is expected in the next year compared to the current price of 73.41.


What is the consensus rating for KYMERA THERAPEUTICS INC (KYMR) stock?

The consensus rating for KYMERA THERAPEUTICS INC (KYMR) is 87.5862 / 100 . This indicates that analysts generally have a positive outlook on the stock.


How many analysts cover KYMERA THERAPEUTICS INC (KYMR) stock?

The number of analysts covering KYMERA THERAPEUTICS INC (KYMR) is 29.